HCPLive Network

Plaque Psoriasis

The US Food and Drug Administration recently announced its approval of a new medication for the treatment of rheumatoid arthritis.
For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.
Individuals with hypertension and those with long-term, regular use of beta-blocker medication may be at increased risk of developing psoriasis flares, according to research published online July 2 in JAMA Dermatology.
As research continues to be done to find the most efficient treatment for patients with plaque psoriasis a study was recently published looking at how the inclusion of topical corticosteroids can benefit the care provided.
For more than 70 years methotrexate has been a popular tool in the prescription toolkit of doctors around the world. However, a recent case report by a team from the United Kingdom showed how important it is for prescribing doctors to also keep a close eye on some of the well-known adverse events associated with the medication.
Study results show that obese patients with psoriatic arthritis who were treated with tumor necrosis factor-alpha blockers who also lost at least 5 percent of their bodyweight from baseline were much more likely to achieve minimal disease activity.
Plaque Psoriasis Upcoming Events
Paris, France
June 11-14, 2014
New York, NY
July 9-12, 2014
Chicago, IL
August 6-10, 2014
Louisville, KY
August 7-9, 2014
Las Vegas, NV
September 12-13, 2014
Sonoma, CA
September 24-27, 2014
Las Vegas, NV
October 16-19, 2014
Dallas, TX
October 24-26, 2014
Boston, MA
November 14-19, 2014
New Orleans, LA
April 27-29, 2015
$AD300x250BB$